Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo. J of Skin. 2023;7(6):s272. doi:10.25251/skin.7.supp.272